- Swedish Orphan Biovitrum (BIOVF, Financial) to repurchase all issued class C shares between July 16 and November 7, 2025.
- The repurchase is part of commitments under the company's long-term incentive programmes.
- After the conversion, Sobi's holdings of common shares will increase to 12,790,468.
Swedish Orphan Biovitrum (BIOVF) has announced its Board of Directors has authorized the repurchase of all issued class C shares. This action follows a resolution from the Annual General Meeting on May 8, 2025, aimed at fulfilling commitments under the company's long-term incentive programmes. The repurchase will occur at 100% of the quotient value, which is approximately SEK 0.55 per share, and is scheduled between July 16 and November 7, 2025.
Upon completion of the repurchase and conversion of class C shares to common shares, Sobi's total holdings of own common shares are expected to increase from 11,377,680 to 12,790,468. This strategic move is designed to secure the company's incentive commitments and illustrates its proactive financial management.
In 2024, Swedish Orphan Biovitrum reported a revenue of SEK 26 billion and employed around 1,900 people globally, highlighting its robust market presence and operational scale. Sobi, a leading global biopharma company, focuses on transformative innovations for people living with rare diseases, reinforcing its dedication to breakthrough advancements in the healthcare sector.
